| Lectures | Speakers | Presentations | Abstracts |
| DAY 1 Tuesday 8 July | |||
| Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | |||
| Chairs: Jerry Nedelman & Eric Nuermberger | |||
| Pretomanid dosing and pharmacokinetics in North American patients with tuberculosis, 2019-2024 | Nicole Maranchick | Abstract | |
| Semi-mechanistic population pharmacokinetic modelling of the novel antituberculosis drug TBAJ-876 and its metabolite M3 in healthy volunteers | Jose Miguel Calderin Miranda | Abstract | |
| Drug interaction potential of sutezolid when combined with bedaquiline, delamanid and moxifloxacin in patients with pulmonary tuberculosis | Ombeni Chimbe | Abstract | |
| Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentrations of rifampicin | Arti Shrivas | Abstract | |
| Rapporteur session | Micha Levi | ||
| Session 2 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB meningitis) | |||
| Chairs: Christine Sekaggya & Rob Aarnoutse | |||
| High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trial | Rovina Ruslami | Abstract | |
| Beyond rifampin: evaluating rifapentine and rifabutin as alternative CNS-targeting treatments for TB meningitis in a murine model | Xueyi Chen | Abstract | |
| Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB | Caryn Upton | Abstract | |
| Bedaquiline central nervous system exposure in a rabbit model of tuberculous meningitis | Sean Wasserman | ||
| Rapporteur session | Sanjay Jain | ||
| Session 3 Clinical TB pharmacology flash talks | |||
| Chairs: Eric Nuermberger | |||
| Need for Healthcare Provider Education in Tuberculosis Patient Care | Summer Walker | ||
| Quantitation of Plasma Bedaquiline Concentrations in Indian MDR-TB Patients Using Liquid Chromatography-Tandem Mass Spectrometry | Rohan Lokhande | Abstract | |
| DAY 2 Wednesday 9 July | |||
| Session 4 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB in pregnancy, lactation and NTM disease) | |||
| Chairs: Caitlin Reed & Charles Peloquin | |||
| Pharmacokinetics and safety of clofazimine in women treated for rifampicin-resistant tuberculosis during pregnancy and the postpartum period | Jennifer Hughes | Abstract | |
| Population pharmacokinetic analysis of levofloxacin in breast milk among patients with rifampicin-resistant tuberculosis | Sharon Sawe | Abstract | |
| Azithromycin exposure and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial infections | Michael Rodgers | Abstract | |
| Rapporteur session | Kelly Dooley | ||
| Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients | |||
| Chairs: Eric Nuermberger & Christine Sekaggya | |||
| Preclinical drug evaluation based on “pathogen health”: drug-specific M. tuberculosis physiologic injury and adaption in ex vivo caseum | Jo Hendrix | Abstract | |
| Development of an Antitubercular Drug Proficiency Testing Program | Raymond Cha | Abstract | |
| Development of an expert-based drug-drug interaction source to facilitate management of co-medications in patients with tuberculosis | David Burger | Abstract | |
| Comparison of salivary and serum levels of isoniazid, rifampicin and pyrazinamide in patients with tuberculosis | Samiksha Ghimire | Abstract | |
| Saliva pharmacokinetic population modelling and simulation of linezolid in multi-drug resistant tuberculosis | Anh Thi Nguyen | Abstract | |
| Rapporteur session | David Ashkin | ||
| Session 6 Clinical TB pharmacology flash talks | |||
| Chairs: Caitlin Reed | |||
| Bedaquiline Dosing and Pharmacokinetics in North American Patients with Tuberculosis, 2019-2024 | Nicole Maranchick | Abstract | |
| Approaches and tools in TB drug development and optimization: Therapeutic Drug Monitoring, pharmacogenetics, biomarkers, etc; innovations and applications | Ronald Arnold Magoba | Abstract | |
| Optimizing the quantitation of rifampicin and pretomanid in human plasma by liquid chromatography tandem mass spectrometry | Lauren Hill | Abstract | |
| Lectures | Speakers | Presentations | Abstracts |
| DAY 1 Tuesday 1 October | |||
| Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | |||
| Chairs: Jerry Nedelman & Eric Nuermberger | |||
| Model-informed once-daily dosing strategy for bedaquiline and delamanid in children, adolescents and adults with tuberculosis | Yu-Jou Lin | Abstract | |
| Linezolid dosing and pharmacokinetics in North American patients with tuberculosis, 2019-2023 | Nicole Maranchick | Abstract | |
| Pharmacogenetics and pharmacokinetics of moxifloxacin in MDR-TB patients in Indonesia: analysis for ABCB1 rs2032582 and SLCO1B1 | Nurul Annisa | Abstract | |
| Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis | Isabella van der Feltz | Abstract | |
| Session 2 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB meningitis) | |||
| Chairs: Caitlin Reed & Christine Sekaggya-Wiltshire | |||
| Pharmacokinetic modelling of rifampicin, isoniazid, pyrazinamide, linezolid and rifabutin in CNS tissues: a rabbit model study of tuberculosis meningitis | Noha Adbelgawad | Abstract | |
| Pharmacokinetic analysis of isoniazid and dexamethasone in adults with tuberculosis meningitis | Jose Miguel Calderin Miranda | Abstract | |
| Pharmacokinetics and safety/tolerability of linezolid in Indonesian TB meningitis patients | Lindsey te Brake | ||
| Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs | Xueyi Chen | Abstract | |
| Rapporteur session | Rob Aarnoutse | ||
| Session 3 Patient populations: pharmacological aspects of specific forms of mycobacterial diseases (TB in pregnancy, children, extrapulmonary TB, NTM disease) | |||
| Chairs: Nicole Maranchick & Ulrika Simonsson | |||
| Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy | Sharon Sawe | Abstract | |
| Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis | Yuanxi Zou | Abstract | |
| Lower dose-adjusted concentrations of rifampicin and pyrazinamide in pulmonary versus extra-pulmonary tuberculosis | Gustav Svärdhagen | Abstract | |
| A loading dose of clofazimine to optimize treatment in patients with nontuberculous mycobacterial diseases | Ralf Stemkens | Abstract | |
| Rapporteur session | Charles Peloquin | ||
| DAY 2 Wednesday 2 October | |||
| Session 4 Approaches and tools in TB drug development and optimization and in treatment of patients | |||
| Chairs: Gerry Davies & Charles Peloquin | |||
| Advancing tuberculosis therapy with co-crystals: a comprehensive review | Shagun Gogna | Abstract | |
| Using machine learning to expedite area under the curve calculation for PK/PD analysis | Abdullah Alsultan | Abstract | |
| Machine-learning time-to-event analysis for prediction of 2-month culture conversion with phase 2a information in tuberculosis drug development | Huifang You | Abstract | |
| On our way to personalized therapy: using therapeutic drug monitoring of moxifloxacin for an external pharmacokinetic model evaluation | Emily Behrens | Abstract | |
| Evaluation of QT prolongation during bedaquiline treatment using a time-varying tuberculosis-specific correction factor (QTcTBT) | Thanakorn Vongjarudech | Abstract | |
| Lectures | Speakers | Presentations | Abstracts | Posters |
| DAY 1 Tuesday 26 September | ||||
| Session 1 Drugs: clinical and non-clinical pharmacology of TB drugs | ||||
| Chairs: Helen McIlleron & Eric Nuermberger | ||||
| Invited lecture. New oxazolidinones: lessons learned about sutezolid and delpazolid | Norbert Heinrich | |||
| Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis | Simon Koele | Abstract | ||
| TBAJ-587 and ERA4TB: a productive clinical development partnership | Almari Conradie | Abstract | ||
| Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis | Ralf Stemkens | Abstract | ||
| Delpazolid population pharmacokinetics in patients with pulmonary tuberculosis | Isabella van der Feltz | Abstract | ||
| Session 2 Patient populations: pharmacological aspects of specific forms of TB | ||||
| Chairs: Jerry Nedelman & Ulrika Simonsson | ||||
| Invited lecture. Insights on TB meningitis treatment from animal models and advanced imaging techniques | Sanjay Jain | |||
| Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of multidrug-resistant tuberculosis in Indonesia | Vycke Yunivita & Fajri Gafar | Abstract | ||
| The association between drug exposure, susceptibility and response and clinical thresholds for pyrazinamide in MDR-TB treatment | Shulan Dong | Abstract | ||
| Population pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy | Manna Semere Gebreyesus | Abstract | ||
| Effect of pregnancy on population pharmacokinetics of levofloxacin in South African adults with rifampicin-resistant tuberculosis | Sharon Sawe | Abstract | ||
| Session 3 Short presentations & pitches for poster viewing | ||||
| Chair: Geraint Davies | ||||
| Population pharmacokinetics of macozinone (PBTZ-169) and active metabolites in healthy volunteers after different oral formulations | Budi Octasari Susanto | Abstract | ||
| A study of the drug interaction potential of TBAJ-876 on CYP3A4 and P-gp substrates in healthy adults | Jerry Nedelman | Abstract | Poster | |
| Pharmacokinetics of levofloxacin during pregnancy and post-partum in persons living with HIV and without HIV and receiving treatment for rifampicin-resistant | Jennifer Hughes | Abstract | Poster | |
| Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis | Noha Abdelgawad | Abstract | Poster | |
| Population pharmacokinetic modelling of pyrazinamide in plasma and cerebrospinal fluid from HIV-associated tuberculosis meningitis adults | Jose Miguel Calderin | Abstract | Poster | |
| Limited sampling strategy and dose evaluation for second-line anti-tuberculosis drugs in patients with type II diabetes mellitus | Jiayi Cao | Abstract | Poster | |
| Evaluating two strategies for the design of pediatric pharmacokinetic studies | Yuanxi Zou | Abstract | Poster | |
| DAY 2 Wednesday 27 September | ||||
| Session 4 The role of consortia in TB drug development | ||||
| Chairs: Rob Aarnoutse & Charles Peloquin | ||||
| ERA4TB | Santiago Ferrer Bazaga | |||
| Unite4TB | Martin Boeree | |||
| PAN-TB | Charles Wells | |||
| Panel discussion on preselected topics & propositions | Coming Soon | |||
| Session 5 Approaches and tools in TB drug development and optimization and in treatment of patients | ||||
| Chairs: Susan Swindells & Paolo Denti | ||||
| Higher-order combination drug regimens and pharmacodynamic markers of response in a mouse tuberculosis infection model | Michael Lyons | Abstract | ||
| Power to identify exposure-response relationships in phase IIa tuberculosis trials with multi-dimensional bacterial load modeling | Simon Koele | Abstract | ||
| Development of a PBPK model for TBAJ-876 within the SIMCYP population-based simulator and subsequent evaluation of DDI liability as a victim of CYP3A4 | Ludwig Vincent | Abstract | ||
| Drug-drug interaction management of bedaquiline and other medications associated with QT-interval prolongation | David Burger | Abstract | ||
| Rifampin dosing and pharmacokinetics from an international TDM service, 2022 | Nicole Maranchick | Abstract | ||
| Saliva-based assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer | Ricky Chen | Abstract | ||
| Session 6 Short presentations & pitches for poster viewing | ||||
| Chair: Jerry Nedelman | ||||
| Co-crystals for tuberculosis | Shagun Gogna | Abstract | Poster | |
| 4β-hydroxycholesterol-to-cholesterol ratio as an endogenous biomarker in human plasma to determine treatment effects of induction and inhibition of CYP3A4 | Yashara Ryan | Abtract | Poster | |
| Population pharmacokinetics of pretomanid in participants of a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Bern-Thomas Nyang'wa | Abstract | Poster | |
| Population pharmacokinetics of clofazimine in a randomised controlled clinical trial for rifampicin-resistant tuberculosis | Ilaria Motta | Poster | ||
| Physico-chemical properties influencing penetration into saliva: a systematic review | Anh Thi Nguyen | Abstract | Poster | |
| Analysis of time to positivity of Mycobacterium tuberculosis in response to treatment for drug susceptible tuberculosis in South African patients | Marie Wijk | Abstract | Poster | |